30-year global healthcare leader developing and building category-defining brands. Current board member of Castle Biosciences (CSTL), a precision diagnostics company.

8-Figure Exit, Novaestiq Corp. Co-Founder & CEO, built the ‘next-generation’ aesthetics platform, raised $10M+ pre-Series A, and FDA approved in Sept ’25.

Member of Galderma’s Executive Leadership Team that crafted the $10.2B sale from Nestle to the EQT Group.

5 years as Galderma’s North American President & GM, scaling Aesthetics, Consumer, and Prescription businesses by 50%+ to $2.1B+ across Dysport®,  Sculptra®, Restylane®, Cetaphil®, Differin®, Proactiv® and Epiduo®.

Attained the 1st FDA-approved RX-to-OTC acne switch in 30 years.

SVP and VP for Novartis across multiple verticals-Pharma, Oncology, Nutrition and Consumer.

‍

25 year entrepreneur and capital markets professional with experience leading a Canadian biotech from startup to IPO, raising $30M in 9 months.

Founder of Conexeu Sciences; led the acquisition of the Conexeu’s global core collagen/ECM IP on an outright basis. (no licensing fees or royalty obligations)

Raised and advised on more than $8M in Conexeu seed capital, coordinating early-stage financings and investor syndicates.

Assembled Conexeu’s world-class management and advisory team across regenerative medicine, aesthetics, wound care, and capital markets.

‍

M.D. Faculty of Medicine,Universidad Nacional Autónoma de México (UNAM), Mexico City.

Ph.D. (Experimental Medicine) Department of Surgery, Plastic and Re-constructive Surgery, UBC.

6 translational tissue-engineering programs (in-vivo bioreactor, liquid skins ubstitute, 3-D bladder/kidney tumor platforms.

10+ pre-clinical / animal studies advancing regenerative surgery toward clinic.

40+ Published peer-reviewed clinical and research papers (plastic surgery, wound healing, stem-cell therapy, 3-D bio-printing)

1 U.S. patent (+ licensed IP) for an implantable modular bio-reactor sold to the U.S. Army

8 Industry & academic collaborations in regenerative medicine.

‍

25+ years in dermatology and aesthetics, he served as CMO of Suneva Medical (acquired by Tiger Bio, 2024) and VP of Medical Affairs for Merz North America, leading the launch of Radiesse.

8 FDA-related post-market / label-expansion programs (Radiesse®, Xeomin®, Belotero®, Instalift®, HD-PRP, etc.)

15 clinical programs in regenerative aesthetics, fillers and thread-lifts.

20+ Published Research Papers (PMMA collagen filler science, wound biology).

25 patents (3 direct-inventor; 22 co-inventor) on aromatic-aldehyde dermatologic therapeutics & ECM biology.

10 Affiliated Aesthetic / Pharma Companies (Merz, Suneva, Endo, Sinclair, Servier, Roche, Cytrellis, Camurus, Paradigm, Premier HC).

‍

‍

Financial executive with nearly 40 years in accounting and tax management.

Co-founded a Canadian biotech developing bio-pharmaceutical products. Deep expertise in small-cap markets, securities regulations, and corporate governance.

Managed audits for multiple go-public transactions, supporting capital raises and growth initiatives.

‍

‍

20+ years of experience in operational excellence, brand development, M&A integration, finance, and commercial growth. Experience includes roles across Fortune 500 and global healthcare organizations. Held multiple positions at Galderma spanning Marketing, Finance, Project Management, Launch Excellence, and Commercial Strategy.

Earlier career included leadership roles in audit, finance, integration, and operations across financial services and investment banking.

Recognized by Fort Worth CEO Magazine as a Top 20 Woman to Watch in Business.

‍

25+ years in finance, transformation, and corporate development, supporting CEOs, boards, and private equity sponsors. 

Transaction experience spans across M&A, licensing, carve-outs, IPO readiness, restructurings, and exits. 

Founder of Allyght Advisory, serving private equity-backed and privately held companies including structuring strategic partnerships and advising executive teams on growth and transaction execution. 

Former Vice President of Corporate Development and Head of Transactions at Galderma, with responsibility for acquisitions, divestitures, licensing agreements, and IPO readiness. 

‍

‍

Chair of the Board with a track record of scaling ventures from startup to IPO, including a biotech that raised $30M in 9 months.

Guided numerous private companies to public listings, generating ~$100Min financing with expertise in IPOs and M&A.

Awarded Canada’s Top 40 Under 40 forleadership at a national start-up.

Active investor and advisor, focused on helping emerging companies transition from private to public markets and achieve successful exits.

‍

Dr. Lorenc is board certified by theAmerican Board of Plastic Surgery, a member of the American Society of PlasticSurgeons, International Society of Aesthetic Plastic Surgery.

Advised J&Jon Evolence collagen filler acquisition ($159M)

10 FDA pivotal trials(supporting regulatory clearances)

25+clinical studies on dermal fillers, neurotoxins, lasers and surgical devices

100+Published Research Papers (peer reviewed aesthetic manuscripts)

39patents covering soft-tissue augmentation, surgical appliances, antimicrobial sutures, collagen formulation.

20+sponsor & industry affiliations—Allergan, Galderma, Merz Aesthetics, Chroma, Teoxane, Krystal Bio

‍

‍

CEO and Chief Investment Officer of 1.2 Capital, an alternative investment management firm.

ResearchGrants awarded from American PhilosophicalAssociation, National Endowment for the Humanities, and NationalEndowment for the Arts.

Lectured at Princeton,Columbia and McGill University

Work featured in multiple outlets including: The Guardian,BBC World, and Time Magazine

‍

Dr.Aaron Farberg is a double board-certified dermatologist and fellowship-trained Mohs surgeon practicing in Texas. He is the ChiefMedical Officer and founder of Bare Dermatology.

14 FDA Phase 3/3b registration‑supporting dermatology trials

35+clinical programs across medical & procedural dermatology biologics.

100+peer‑reviewed publications spanning skin cancer diagnostics and device‑based care.

1patent — Device to Aid in ArterialMicrovascular Anastomosis (US2016/50037).

20+sponsor & industry affiliations (trial sponsors and advisory roles) — Sanofi, AbbVie, Janssen, Lilly/Dermira, UCB, Incyte, Regeneron, Apogee, Alumis, Takeda, Novartis, Merck,Roche, Clinuvel, Blueprint Medicines; plus advisory, Galderma, Sun Pharma, Castle Biosciences, SurgiVance.

‍

Bastiani-Posner is a seasoned financial expert and C-suite executive with more than 20 years of leadership experience across Fortune 500 companies and research organizations. She currently serves as Executive Vice President and Chief Financial Officer of Kyowa Kirin North America, where she helps oversee approximately $1.2 billion in annual revenue.  Ana brings extensive experience in healthcare operations, financial strategy, mergers and acquisitions, and corporate governance, with previous senior leadership roles at Allergan, New York Genome Center, Schering-Plough, and Novartis.

Burke is a finance executive with experience spanning public companies, private equity-backed organizations, and privately held businesses. April currently serves as Executive Vice President and Chief Financial Officer of Lucid Hearing, where she brings expertise in capital allocation, financial operations, mergers and acquisitions, IPO readiness and organizational growth initiatives.

Costa is an investor, operator, and growth equity executive with fifteen years of experience across private equity, investment banking, and military leadership. He is the Co-Managing Partner of RX3 Growth Partners, a consumer-focused growth equity firm investing in health, wellness, and active-lifestyle brands, where he leads investments and serves on the boards of multiple portfolio companies, including Therabody. He previously held investment banking roles at Morgan Stanley and J.P. Morgan, advising companies on capital formation, public offerings, and M&A. Earlier in his career, Costa served as a Captain in the United States Air Force. He brings to the Board extensive capital markets expertise, financial oversight experience, and the operational discipline of his military service.